Crit Care Med:脓毒症与微血管脑损伤的关系

2019-08-12 xing.T MedSci原创

由此可见,通过微血管梗塞评估,脓毒症与中度至重度血管脑损伤特异性相关。对于大脑皮质内的微小梗塞,这种关联更强,那些经历严重脓毒症住院治疗的患者在调整分析中有中度至重度大脑皮质损伤证据的可能性超过两倍。需要进一步研究以确定脓毒症和微小梗塞之间的相关机制。

许多败血症的幸存者会出现长期认知障碍,但这种关联的机制仍然未知。近日,危重病医学领域权威杂志Critical Care Medicine上发表了一篇研究文章,这项研究的目的是确定脓毒症是否与脑微小梗塞相关。

该研究为包含529名参与者的回顾性队列研究,这些参与者住居于华盛顿,大于或等于65岁,且在研究开始时无痴呆症并且死后接受过大脑尸检。研究人员使用行政数据确定晚期脓毒症住院治疗情况,在研究期间确定了89名至少住院1次的脓毒症患者,其中80名患者在住院后存活,出院后死亡时间的中位数为169天。

30%至少住院1次的脓毒症患者有超过2处微小梗塞,相比于没有住院的脓毒症的患者,其为19%(χ2p=0.02); 脓毒症住院患者中有20%的患者大脑皮层中有超过2处微小梗塞,而相比于没有住院的脓毒症的患者,其为10%(χ2p=0.01)。超过2处微小梗塞调整后的相对风险为1.61(95%CI为1.01-2.57; p=0.04); 在大脑皮质中具有超过2处微小梗塞的相对风险是2.12(95%CI为1.12-4.02; p=0.02)。路易体在脓毒症患者中较少见。

由此可见,通过微血管梗塞评估,脓毒症与中度至重度血管脑损伤特异性相关。对于大脑皮质内的微小梗塞,这种关联更强,那些经历严重脓毒症住院治疗的患者在调整分析中有中度至重度大脑皮质损伤证据的可能性超过两倍。需要进一步研究以确定脓毒症和微小梗塞之间的相关机制。 

原始出处:

Ehlenbach, William J. et al.Association Between Sepsis and Microvascular Brain Injury.critical care medicine.2019. https://journals.lww.com/ccmjournal/Abstract/onlinefirst/Association_Between_Sepsis_and_Microvascular_Brain.95871.aspx

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1365375, encodeId=858513653e5b3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397804, encodeId=5187139e80447, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609933, encodeId=195b1609933be, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371196, encodeId=47403e1196b6, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Tue Aug 13 08:06:18 CST 2019, time=2019-08-13, status=1, ipAttribution=)]
    2019-08-14 mgqwxj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1365375, encodeId=858513653e5b3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397804, encodeId=5187139e80447, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609933, encodeId=195b1609933be, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371196, encodeId=47403e1196b6, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Tue Aug 13 08:06:18 CST 2019, time=2019-08-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1365375, encodeId=858513653e5b3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397804, encodeId=5187139e80447, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609933, encodeId=195b1609933be, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371196, encodeId=47403e1196b6, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Tue Aug 13 08:06:18 CST 2019, time=2019-08-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1365375, encodeId=858513653e5b3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397804, encodeId=5187139e80447, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609933, encodeId=195b1609933be, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 14 03:17:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371196, encodeId=47403e1196b6, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Tue Aug 13 08:06:18 CST 2019, time=2019-08-13, status=1, ipAttribution=)]
    2019-08-13 184****9840

    学习了,谢谢分享。

    0

相关资讯

Clinica Chimica Acta:采用新型LC-MS/MS法测定脓毒症休克时血浆缓激肽浓度

缓激肽是炎症和血管通透性的重要介质,在感染性休克的发生过程中可能发挥重要作用。然而,采用免疫学方法测定缓激肽可能受到干扰,且缺乏特异性。因此本研究建立了血浆缓激肽的液相色谱 · 2019-08-06

-->

脓毒症休克中的血管加压素: 我们所知道的,下一步该去哪里?

去甲肾上腺素是分布性休克患者最常用的血管升压药。然而,一项研究表明,在美国医院约有17.2%的脓毒性休克患者使用血管加压素,通常联合儿茶酚胺类。在纳入来自澳大利亚、英国、新西兰、沙特阿拉伯和丹麦的患者的ADRENAL试验中,有相似的使用水平,约有16.8%的患者,在基线水平时使用了血管加压素。另一方面,在APROCCHSS一项欧洲试验中,仅有0.08%的患者,在基线水平时接受了血管加压素。这种多变

Blood:脓毒症时,血小板的转录本和翻译组均发生明显改变

越来越多的人认识到血小板在脓毒症的病理生理过程中具有重要的作用,但这一点目前还没有明确的定义。脓毒症是否会改变人类血小板的转录和翻译尚未明确。近日,《Blood》杂志上发表一篇文章,研究人员利用RNA测序和核糖体足迹分析来研究脓毒症患者和健康献血者的血小板的转录组和翻译组。研究人员从脓毒症患者的血小板中共鉴定出1806个表达具有显著差异的转录本(FDR < 0.05)。在脓毒症过程中,血小板

15%的败血症幸存者在离开医院的一年内死亡

伦敦国王学院研究人员对败血症幸存者的数据分析发现,脓毒症存活的患者死亡风险可能高达五年。

Crit Care:造影剂对脓毒症相关的急性肾损伤患者肾功能和预后影响

由此可见,单次给予造影剂与脓毒症患者AKI恶化或短期/长期死亡率增加无关。

Anesth Analg:脓毒症干预治疗与住院期间患者死亡率的关系:真实世界数据回顾性分析

脓毒症是对感染的全身反应,可导致组织损伤,器官衰竭和死亡。已经努力制定循证干预措施,以在疾病早期确定和控制脓毒症,以减少脓毒症相关的发病率和死亡率。我们用可靠的观察数据方法评估了微创脓毒症干预组与住院死亡率之间的关系。